OBJECTIVE: Pig-to-primate renal xenotransplantation is plagued by early antibody-mediated graft loss which precludes clinical application of renal xenotransplantation. We evaluated whether temporary complement inhibition with anti-C5 antibody Tesidolumab could minimize the impact of early antibody-mediated rejection in rhesus monkeys receiving pig kidneys receiving costimulatory blockade-based immunosuppression. METHODS: Double (Gal and Sda) and triple xenoantigen (Gal, Sda, and SLA I) pigs were created using CRISPR/Cas. Kidneys from DKO and TKO pigs were transplanted into rhesus monkeys that had the least reactive crossmatches. Recipients received anti-C5 antibody weekly for 70 days, and T cell depletion, anti-CD154, mycophenolic acid, and steroids as baseline immunosuppression (n = 7). Control recipients did not receive anti-C5 therapy (n = 10). RESULTS: Temporary anti-C5 therapy reduced early graft loss secondary to antibody-mediated rejection and improved graft survival (P < 0.01). Deleting class I MHC (SLA I) in donor pigs did not ameliorate early antibody-mediated rejection (table). Anti-C5 therapy did not allow for the use of tacrolimus instead of anti-CD154 (table), prolonging survival to a maximum of 62 days. CONCLUSION: Inhibition of the C5 complement subunit prolongs renal xenotransplant survival in a pig to non-human primate model.
OBJECTIVE: Pig-to-primate renal xenotransplantation is plagued by early antibody-mediated graft loss which precludes clinical application of renal xenotransplantation. We evaluated whether temporary complement inhibition with anti-C5 antibody Tesidolumab could minimize the impact of early antibody-mediated rejection in rhesus monkeys receiving pig kidneys receiving costimulatory blockade-based immunosuppression. METHODS: Double (Gal and Sda) and triple xenoantigen (Gal, Sda, and SLA I) pigs were created using CRISPR/Cas. Kidneys from DKO and TKO pigs were transplanted into rhesus monkeys that had the least reactive crossmatches. Recipients received anti-C5 antibody weekly for 70 days, and T cell depletion, anti-CD154, mycophenolic acid, and steroids as baseline immunosuppression (n = 7). Control recipients did not receive anti-C5 therapy (n = 10). RESULTS: Temporary anti-C5 therapy reduced early graft loss secondary to antibody-mediated rejection and improved graft survival (P < 0.01). Deleting class I MHC (SLA I) in donor pigs did not ameliorate early antibody-mediated rejection (table). Anti-C5 therapy did not allow for the use of tacrolimus instead of anti-CD154 (table), prolonging survival to a maximum of 62 days. CONCLUSION: Inhibition of the C5 complement subunit prolongs renal xenotransplant survival in a pig to non-human primate model.
Authors: Luz M Reyes; Jose L Estrada; Zheng Yu Wang; Rachel J Blosser; Rashod F Smith; Richard A Sidner; Leela L Paris; Ross L Blankenship; Caitlin N Ray; Aaron C Miner; Matthew Tector; A Joseph Tector Journal: J Immunol Date: 2014-10-22 Impact factor: 5.422
Authors: Gregory R Martens; Luz M Reyes; Ping Li; James R Butler; Joseph M Ladowski; Jose L Estrada; Richard A Sidner; Devin E Eckhoff; Matt Tector; A Joseph Tector Journal: Transplantation Date: 2017-04 Impact factor: 4.939
Authors: Bonnie E Lonze; Vasishta S Tatapudi; Elaina P Weldon; Elijah S Min; Nicole M Ali; Cecilia L Deterville; Bruce E Gelb; Judith A Benstein; Nabil N Dagher; Ming Wu; Robert A Montgomery Journal: Ann Surg Date: 2018-09 Impact factor: 12.969
Authors: Andrew B Adams; Steven C Kim; Gregory R Martens; Joseph M Ladowski; Jose L Estrada; Luz M Reyes; Cindy Breeden; Allison Stephenson; Devin E Eckhoff; Matt Tector; Alfred Joseph Tector Journal: Ann Surg Date: 2018-10 Impact factor: 12.969
Authors: Hao Feng; Tao Li; Jiaxiang Du; Qiangbing Xia; Lu Wang; Song Chen; Lan Zhu; Dengke Pan; Yi Wang; Gang Chen Journal: Front Immunol Date: 2022-03-29 Impact factor: 7.561
Authors: Tao Li; Hao Feng; Jiaxiang Du; Qiangbing Xia; David K C Cooper; Hongtao Jiang; Songzhe He; Dengke Pan; Gang Chen; Yi Wang Journal: Front Immunol Date: 2022-03-10 Impact factor: 7.561